secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062005
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences reports Q3 2023 net loss $7.1M; cash $20M; advances cytisinicline trials
--------------------------------------------------------------------------------

- Cash and restricted cash $20.0M as of Sep 30, 2023; net loss $7.1M in Q3 2023.
- ORCA-2 Phase 3 smoking cessation results published in JAMA; cytisinicline showed significant efficacy.
- Completed dosing of three NDA-supportive studies (QT, PK in smokers, renal impairment); data due early 2024.
- Phase 2 ORCA-V1 results presented: 2.6-fold increase in vaping cessation odds vs placebo.
- Shares outstanding: 21,165,760 as of Nov 9, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017023062005/0000950170-23-062005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017023062005/achv-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer